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signature could improve diagnostic accuracy, allow more rapid intervention in critically ill children, and reduce the need for lung biopsy in those patients in whom radiologic and genetic studies are indeterminate.
The protein signatures identified in this study also offer exciting potential insights into disease mechanisms and possible new therapeutic targets. This is particularly important for NEHI, which, although relatively common (by chILD standards), is poorly understood from a mechanistic standpoint. Lung biopsies performed on patients with NEHI show increased pulmonary neuroendocrine cells, which function as innervated sensory cells within the lungs (11) . However, it is unclear how abnormalities within this cell type lead to hypoxemia, as the lung parenchyma in patients with NEHI is almost normal on biopsy (2) . The cell signaling and metabolic pathways identified in this study offer new pathways to investigate and may provide mechanistic insight. Interestingly, the proteomic signatures suggested two distinct endotypes in NEHI. This may indicate that NEHI represents two separate disorders, although both had similar clinical outcomes. In surfactant protein deficiency, the identification of pathways involved in fibrosis offers hope that work in adult inflammatory-fibrosis lung models may be relevant to these rare disorders. This is particularly important, as many patients with surfactant dysfunction, particularly those with pathologic variants in ABCA3 (ATP-binding cassette subfamily A member 3), have significant mortality (12) , and therefore medications that slow progression are needed. Also, most patients with surfactant dysfunction that present in childhood have progressive disease, so antifibrotic medications developed for adult ILD may be beneficial.
Although the findings of this study represent an exciting advance in chILD, the conclusions must be viewed with some caution, as the study was small (understandable, given the low prevalence of chILD) and lacked an independent validation cohort. Although the authors used appropriate statistical methods to minimize bias, the relationships between the identified pathways and disease pathophysiology will remain uncertain until validated through independent study. Furthermore, many of the markers elevated in the surfactant dysfunction group have also been associated with neutrophilic airway inflammation in other diseases (13) , which was elevated in this cohort. Further investigation will be needed to identify which are specific to surfactant dysfunction.
Overall, this study by Deterding and colleagues offers an exciting first step toward developing biomarker-based evaluation of chILD. Although bronchoscopy and BAL is not without risk, it offers a significant benefit over lung biopsy, particularly in critically ill children. With appropriate validation, this study could represent a critical first step toward developing improved biomarker-based diagnostic and treatment strategies for pediatric rare lung disease. n 
